Orchestra BioMed Raises $80.5 Million in Offering

The company sold 17.25 million shares at $5 each after completing enrollment in its Phase 3 BACKBEAT trial of AVIM Therapy.

Updated on Nov. 19, 2026 in Healthcare

Orchestra BioMed Raises $80.5 Million in Offering

Orchestra BioMed closed an underwritten public offering on November 9, selling 17.25 million common shares at $5 each for approximately $80.5 million in net proceeds. The underwriters fully exercised their option to purchase additional shares.

Why it matters

The financing follows completion of patient enrollment in the BACKBEAT trial and extends the company's cash runway to cover anticipated clinical and regulatory milestones. The funding is expected to support operations through 2028.

Orchestra BioMed's third-quarter net loss attributable to common stockholders was $19.6 million, or $0.30 per share, while research and development expenses rose 26% to $17.7 million and selling, general and administrative expenses fell 21% to $5.6 million. The company received a $6.1 million milestone payment on September 14 tied to Haemonetics' acquisition of Vivasure Medical, and the source does not specify how the new proceeds will be split among research programs.

The players

Orchestra BioMed Holdings Inc.

Orchestra BioMed is a medical technology company developing cardiovascular and renal therapies, including the AVIM Therapy device, and is based in New Hope, Pennsylvania.

Medtronic plc

Medtronic is a global medical device manufacturer and is the partner that plans to submit a supplement for AVIM Therapy following positive BACKBEAT results.

The details

Orchestra BioMed completed enrollment in the global Phase 3 BACKBEAT trial, randomizing 349 patients across 92 clinical sites in 15 countries. AVIM Therapy, the company's device, lowers blood pressure by modifying the timing between atrial and ventricular contractions through an implanted pacemaker.

Timeline

  1. September 14, 2026: Received $6.1 million milestone payment from the Vivasure transaction.

  2. September 30, 2026: Held $101.9 million in cash, cash equivalents and marketable securities.

  3. November 9, 2026: Closed underwritten public offering of 17.25 million shares.

  4. November 12, 2026: Held an investor R&D presentation in New York City.

  5. May 2027: Planned presentation of primary endpoint results at the Heart Rhythm Society's annual meeting.

Healthcare Pipeline

The financing advances AVIM Therapy, a pacemaker-based hypertension treatment, toward a possible Medtronic regulatory supplement after the BACKBEAT trial reports its primary results at the Heart Rhythm Society meeting in May 2027. Its progress is measured against the broader pipeline of device-based treatments for high blood pressure that do not rely on daily medication.

For patients with hypertension, AVIM Therapy would represent a device-based option that works through the timing of heart contractions rather than daily medication, though it is not yet approved. The trial results and any regulatory decision will determine whether it becomes available to patients.

The takeaway

Investors and patients should watch the BACKBEAT primary endpoint results expected in May 2027, since they will determine whether AVIM Therapy advances toward regulatory submission. The company's cash position and funding timeline provide a clearer picture of how long development can continue before those results arrive.

What happens next

Orchestra BioMed plans to present primary endpoint results from the BACKBEAT trial at the Heart Rhythm Society's annual meeting in May 2027, and Medtronic plans to submit a supplement for AVIM Therapy if those results are positive.

Further reading

For related coverage, see Healthcare in the business section.

Source note: This article includes information reported by MyChesCo.